Retinal Biologics Market Size, Regional Insights and Strategic Developments

Introduction

• Research Objective
• Scope of the Study
• Definition and Taxonomy

Research Methodology

• Research Approach
• Data Sources
• Assumptions

Executive Summary

• Synopsis
• Analyst Recommendations

Market Overview 

• Market Dynamics
  • Market Drivers
  • Market Restraints
  • Market Opportunities
• Value Chain Analysis
  • Raw Material Sourcing
  • Manufacturing Process
  • Logistics & Transportation
  • Buyer Preferences
• Trends
  • Market Trends
  • Technological Trends
• Porter’s Five Forces Analysis
  • Bargaining Power of Suppliers
  • Bargaining Power of Buyers
  • Threat of Substitute
  • Threat of New Entrants
  • Degree of Competition
• PESTLE Analysis for 5 Leading Countries
  
  • Regulatory Framework for Leading Countries/Regions
  • Supply Demand Analysis
  • Production & Consumption Statistics
  • Export Import Statistics
  • Price Trend Analysis

Global Retinal Biologics Market Assessment

• Overview
• Global Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
  • VEGF-A Antagonist
  • TNF-A Inhibitor
• Global Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
  • Macular Degeneration
  • Diabetic Retinopathy
  • Uveitis
  • Others
• Global Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Region (2021 – 2033)
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America Retinal Biologics Market Assessment

• Overview
• North America Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
  • VEGF-A Antagonist
  • TNF-A Inhibitor
• North America Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
  • Macular Degeneration
  • Diabetic Retinopathy
  • Uveitis
  • Others
• North America Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Europe Retinal Biologics Market Assessment

• Overview
• Europe Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
  • VEGF-A Antagonist
  • TNF-A Inhibitor
• Europe Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
  • Macular Degeneration
  • Diabetic Retinopathy
  • Uveitis
  • Others
• Europe Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Asia Pacific Retinal Biologics Market Assessment

• Overview
• Asia Pacific Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
  • VEGF-A Antagonist
  • TNF-A Inhibitor
• Asia Pacific Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
  • Macular Degeneration
  • Diabetic Retinopathy
  • Uveitis
  • Others
• Asia Pacific Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Latin America Retinal Biologics Market Assessment

• Overview
• Latin America Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
  • VEGF-A Antagonist
  • TNF-A Inhibitor
• Latin America Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
  • Macular Degeneration
  • Diabetic Retinopathy
  • Uveitis
  • Others
• Latin America Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Middle East & Africa Retinal Biologics Market Assessment

• Overview
• Middle East & Africa Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
  • VEGF-A Antagonist
  • TNF-A Inhibitor
• Middle East & Africa Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
  • Macular Degeneration
  • Diabetic Retinopathy
  • Uveitis
  • Others
• Middle East & Africa Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Company Profiles

• Santen Pharmaceutical Co., Ltd (Japan)
  • Company Overview
  • Geographic Footprints
  • Financial Performance
  • Product Portfolio
  • SWOT Analysis
  • R&D Efforts
  • Recent Developments & Strategic Collaborations
    • Product Launch/M&A/Technical Collaboration
• AbbVie Inc. (U.S.)
• Aurobindo Pharma (India)
• Bayer AG (Germany)
• Bayer AG (Germany)
• Fresenius Kabi AG (Germany)
• AstraZeneca (U.K.)
• Teva Pharmaceuticals Industries Ltd. (Israel)
• Sun Pharmaceutical Industries Ltd. (India)
• Merck & Co Inc. (U.S.)
• Boehringer Ingelheim International GmbH. (Germany)
• Amgen Inc. (U.S.)
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• Kodiak Sciences Inc. (U.S.)

Conclusion & Recommendations